Cellular Immune Responses in Patients with Hepatitis B Surface Antigen Seroclear

StephenW

http://7thspace.com/headlines/372788/cellular_immune_responses_in_patients_with_hepatitis_b_surface_antigen_seroclearance_induced_by_antiviral_therapy.html
[An interesting article, report seems to be incomplete. Best to read the whole paper.
StephenW]
Cellular Immune Responses in Patients with Hepatitis B Surface Antigen Seroclearance Induced by Antiviral Therapy
The mechanisms by which chronic hepatitis B is completely resolvedthrough antiviral therapy are unknown, and the contribution of acquiredT cell immunity to hepatitis B surface antigen (HBsAg) seroclearancehas not been investigated. Therefore, we measured the T-cell responsesto core and envelope antigens in patients with HBsAg seroclearance.

Methods: Fourteen subjects with HBsAg seroclearance followingantiviral treatment for chronic hepatitis B, 7 HBeAg-positiveimmunotolerant HBV carriers and 9 HBeAg-negative inactive HBsAgcarriers were recruited.

HBV-specific T-cell responses to recombinant HBV core (rHBcAg) andenvelope (rHBsAg) proteins and pools of core and envelope peptides weremeasured using an ELISPOT assay detecting interferon-gamma andintracellular cytokine staining (ICS) assays detecting interferon-gammaor interleukin 2.

Results: Interferon-gamma ELISPOT assays showed a lowfrequency of weak responses to the rHBsAg and S peptide pool in theHBsAg seroclearance group, and the response frequency to the rHBcAg andthe C peptide pool was higher than to the rHBsAg (P<0.001) and Speptide pool (P=0.001) respectively. A higher response frequency to Cthan S peptide pools was confirmed in the interferon-gamma ICS assaysfor both CD4+ (P=0.033) and CD8+ (P=0.040) T cells in the HBsAgseroclearance group.

The responses to C and S antigens in the inactive carriers were similar.

Conclusions: There was a low frequency of CD4+ and CD8+ T cellimmune responses to envelope antigens in Chinese subjects with HBsAgseroclearance following antiviral therapy. It is unlikely that theseimmune responses are responsible for HBsAg seroclearance in thesesubjects.

Author: Minfeng LiangShiwu MaXiaoxiong HuBin ZhouJunchangZhangJinjun ChenZhanhui WangJian SunXiaolin ZhuWilliam AbbottJinlin Hou
Credits/Source: Virology Journal 2011, 8:69
[一篇有用的文章，报告似乎是不完整的。最好多看整份文件。
StephenW]
细胞免疫应答与乙肝表面抗原血清廓清了抗病毒治疗的患者诱导
以何种慢性乙型肝炎抗病毒治疗是完全通过解决机制不明，后天免疫T细胞对乙肝表面抗原的贡献（HBsAg）的血清廓清并没有受到调查。因此，我们衡量的T -细胞的反应，患者和信封核心抗原与HBsAg血清廓清。

方法：乙肝表面抗原血清廓清以下十四个科目的慢性乙型肝炎抗病毒治疗，7 e抗原阳性的乙肝病毒携带者的免疫耐受和9 e抗原阴性的非活动性HBsAg携带者进行问卷调查。

乙肝病毒特异性T细胞的反应，重组乙肝病毒核心（rHBcAg）及信封（rHBsAg）蛋白质和肽的核心和信封池测定采用酶联免疫斑点法检测了γ-干扰素和细胞内细胞因子染色（ICS）的化验检测干扰素-γ或白细胞介素2。

结果：干扰素-γELISPOT法检测呈弱反应低频的rHBsAg和S组的乙肝表面抗原血清廓清肽池，响应频率到rHBcAg和C肽池比对rHBsAg性（P“0.001），高和S肽池（P值0.001）。较高的响应频率为C肽池比S证实了干扰素-γ为ICS的检测的CD4 +性（P = 0.033）和CD8 +性（P = 0.040），在乙肝表面抗原血清廓清组T细胞。

对处于非活动载体C和S抗原反应相似。

结论：有一个低频的CD4 +和乙肝表面抗原血清廓清抗病毒治疗后CD8 + T细胞在中科信封抗原的免疫反应。这是不可能的这些免疫反应对乙肝表面抗原血清廓清这些科目负责。

作者：民丰LiangShiwu MaXiaoxiong湖滨ZhouJunchang ZhangJinjun ChenZhanhui望间SunXiaolin ZhuWilliam AbbottJinlin侯
学分/来源：病毒学杂志2011，8:69